Skip to Main Content

The U.S. government will spend $3 million to find out if marijuana can relieve pain, but none of the money will be used to study the part of the plant that gets people high.

Nine research grants announced Thursday are for work on CBD, the trendy ingredient showing up in cosmetics and foods, and hundreds of less familiar chemicals. THC research was excluded.


The federal government still considers marijuana an illegal drug, but more than 30 states allow it use for a range of medical problems, some without good evidence.

The science is strongest for chronic pain, the most common reason people give when they enroll in state-approved medical marijuana programs. But little is known about which parts of marijuana are helpful and whether the intoxicating effects of THC can be avoided.

“The science is lagging behind the public use and interest. We’re doing our best to catch up here,” said Dr. David Shurtleff, deputy director of the National Center for Complementary and Integrative Health, which is funding the projects.


STAT reporter Nick Florko examines everything you need to know about CBD and how the Trump administration is likely to regulate these products. Alex Hogan/STAT

THC has been investigated extensively, Shurtleff said, and its potential for addiction and abuse make it unsuitable for treating pain.

Other federal agencies have supported marijuana research, but much of the focus has been on potential harms. Shurtleff said the grants answer the call in a 2017 National Academies of Sciences, Engineering, and Medicine report, which concluded a lack of marijuana research poses a public health risk.

Another driver is the nation’s opioid addiction crisis, with its roots in overuse of prescription painkillers. The crisis has sparked new scientific interest in marijuana’s pain-easing properties.

Dr. Judith Hellman, a grant recipient from University of California, San Francisco, said scientists need to better understand pain and to find more ways to treat it. “It’s very exciting to have the opportunity to do that,” she said.

Hellman’s research involves the body’s ability to produce signaling molecules similar to marijuana’s ingredients. Her and Dr. Mark Schumacher’s work involves human immune cells in the lab, then tests on mice.

Human test subjects will be involved in only one of the grant projects. University of Utah researcher Deborah Yurgelun-Todd will scan the brains of human volunteers with lower back pain to see how CBD extract — mixed with chocolate pudding — affects pain-signaling pathways. Half the volunteers will get pudding without CBD as a control group.

Two more human studies may be funded in a second round of grant awards, NCCIH said.

In July, the National Institute on Drug Abuse said it would grow 2,000 kilograms (4,409 pounds) of marijuana this year at the University of Mississippi, which holds the sole federal contract for producing research cannabis. Those plants won’t be used in many of the new projects, which instead will use lab-made versions of the chemicals.

Researchers in Illinois hope to create a library of useful compounds found in cannabis plants.

“We make them from scratch and test them one by one,” said David Sarlah of the University of Illinois. Marijuana contains such tiny amounts of the interesting ingredients that it’s too costly and time consuming to isolate enough for research, Sarlah said.

Sarlah, an organic chemist, will make the chemicals. His colleague Aditi Das will run tests to see how they react with mouse immune cells.

“There are so many beneficial effects that patients report. We need to know the science behind it,” Das said.

— Carla K. Johnson

  • In the world of commercial marijuana sales there are far too many “gaps”; both in valid unbiased information and reliable, independent truthful studies.

    The media can start by not equating CBD oils with THC. Legitimate versions of CBD health products are derived exclusively from HEMP — which absolutely does not contain the high-inducing THC properties of a Cannibus plant.

  • A meagre $3M is such a small drop in the giant bucket of research needed for the merits of the cannabis plant, that is is a pathetic token of BAM interest (Bare A** Minimum). At government level in the US, the fear, anxiety, stgima, and stubborn old-fashioned resistance to real modern swift and efficient research would be hilarious, were it not that so many patients keep suffering who otherwise would legally benefit …………

  • Thc’s addiction and misuse potential? I’d like to see the science behind that statement. The opioids these guys allowed kill more people every minute than thc products have ever. Why drop $3 million if you plan on ignoring the data anyway?? Whether they like it or not MJ will be legalized in the next 2-10 years. No fake science needed to see the benefits when millions are already getting relief.

    • CBD has absolutely no high feeling. It is not a gateway drug due to it not being on the same level as opiates. Marijuana users that have not been influenced by addicts of opiates remain solely users of Marijuana. Another huge problem is that marijuana users may use marijuana until they are hurt and prescribed opiate medication and this in turn crests an opiate addict. You are absolutely right without studies you cannot accuse marijuana as being a gateway drug there is no study or no proof to this accusation.

Comments are closed.